Patents by Inventor Mark Oldham
Mark Oldham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240342287Abstract: A kit for use in performing a cancer treatment, having a vial containing a phosphor-containing drug activator, wherein the phosphor-containing drug activator is present in the vial at a dosage level that is correlated with a size of tumor to be treated, and a container containing the vial; wherein the phosphor-containing drug activator contains an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; where the two or more phosphors include Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating and a diamond-like carbon coating.Type: ApplicationFiled: June 24, 2024Publication date: October 17, 2024Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. BOURKE, JR., Zakaryae FATHI, Wayne F. BEYER, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
-
Patent number: 11992697Abstract: A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body; infusing the diseased site with a photoactivatable drug; applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume, wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.Type: GrantFiled: March 21, 2022Date of Patent: May 28, 2024Inventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, Jr., Harold Walder, Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Publication number: 20240042233Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: ApplicationFiled: July 27, 2023Publication date: February 8, 2024Applicants: Immunolight, LLC, DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. BOURKE, JR., Zakaryae FATHI, Wayne F. BEYER, JR., Mark DEWHIRST, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
-
Patent number: 11865359Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: GrantFiled: December 27, 2019Date of Patent: January 9, 2024Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr., Mark Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
-
Patent number: 11786595Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: GrantFiled: April 12, 2021Date of Patent: October 17, 2023Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
-
Patent number: 11577092Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.Type: GrantFiled: August 1, 2017Date of Patent: February 14, 2023Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne Beyer, Mark Oldham, Justus Adamson, Paul Yoon
-
Publication number: 20220226666Abstract: A method for treating a diseased site in a human or animal body is provided which includes injecting in a diseased site one or more phosphors which are capable of emitting ultraviolet or visible light into the body; infusing the diseased site with a photoactivatable drug; applying an initiation energy from an initiation energy source comprising an x-ray, gamma ray, or electron source to thereby initiate emission of ultraviolet or visible light into the body; and controlling a dose of the initiation energy with a processor to produce (i) a cytotoxicity inside the diseased site of greater than 20% or (ii) a day-25 stable tumor volume, wherein the processor is programmed to apply the initiation energy in a pulsed manner, wherein the initiation energy is delivered in either (i) a radiograph mode, or (ii) a pulsed fluoroscopy mode.Type: ApplicationFiled: March 21, 2022Publication date: July 21, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, JR., Harold Walder, Mark Dewhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Patent number: 11305131Abstract: A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.Type: GrantFiled: August 29, 2019Date of Patent: April 19, 2022Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Frederic A. Bourke, Jr., Harold Walder, Mark DeWhirst, Neil L. Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada
-
Publication number: 20220080045Abstract: A method for treating a disease in a subject in need thereof is provided involving infusing 8-methoxypsoralen (8-MOP) and a phosphor-containing drug activator into a diseased site in the subject; and delivering a dose of x-rays to the subject for production of the ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose including a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor, wherein the phosphor-containing drug activator includes an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; the two or more phosphors including Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating or a diamond-like carbon coating.Type: ApplicationFiled: November 30, 2021Publication date: March 17, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. BOURKE, JR., Zakaryae FATHI, Wayne F. BEYER, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
-
Publication number: 20220062419Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: ApplicationFiled: April 12, 2021Publication date: March 3, 2022Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark OLDHAM, Justus ADAMSON, Mark W. DEWHIRST, Paul YOON, Harold WALDER, Frederic A. Bourke, JR., Zakaryae FATHI, Wayne F. BEYER, JR.
-
Patent number: 11260129Abstract: A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier.Type: GrantFiled: February 2, 2017Date of Patent: March 1, 2022Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne Beyer, Mark Oldham, Justus Adamson, Michael Nolan
-
Patent number: 11207409Abstract: A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.Type: GrantFiled: May 30, 2018Date of Patent: December 28, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Frederic A. Bourke, Jr., Mark Dewhirst, Neil Spector, Paul Yoon, Justus Adamson, David Alcorta, Kim Lyerly, Leihua Liu, Takuya Osada, Mark Oldham, Zakaryae Fathi, Wayne F. Beyer, Harold Walder
-
Patent number: 11135294Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.Type: GrantFiled: October 26, 2016Date of Patent: October 5, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Mark W. Dewhirst, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer, Jr.
-
Publication number: 20210236855Abstract: Radiotherapy quality assurance (QA) systems and methods are provided that incorporate a shared frame of reference between a treatment plan and a measured dose distribution that allows for 3D dosimetry measurements. An on-board imaging system may provide a shared frame of reference with the radiotherapy treatment system. A dosimeter is also provided for use with the QA systems and methods. The QA systems and methods can be applied as an end-to-end test to evaluate specific parameters of a radiation therapy treatment system, such as an external beam radiotherapy system, including spatial accuracy, isocenter verification and dosimetric accuracy.Type: ApplicationFiled: May 3, 2019Publication date: August 5, 2021Inventors: Justus ADAMSON, Mark OLDHAM, Jaclyn CARROLL, Michael TRAGER, Andrew JIRASEK, Michelle HILTS
-
Patent number: 10940329Abstract: A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug.Type: GrantFiled: November 21, 2017Date of Patent: March 9, 2021Assignees: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Mark Oldham, Justus Adamson, Paul Yoon, Harold Walder, Frederic A. Bourke, Jr., Zakaryae Fathi, Wayne F. Beyer
-
Publication number: 20200282056Abstract: A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier.Type: ApplicationFiled: February 2, 2017Publication date: September 10, 2020Applicants: IMMUNOLIGHT, LLC, DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. BOURKE, JR., Zakaryae FATHI, Wayne BEYER, Mark OLDHAM, Justus ADAMSON, Michael NOLAN
-
Publication number: 20200222711Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: ApplicationFiled: December 27, 2019Publication date: July 16, 2020Applicants: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Harold WALDER, Frederic A. Bourke, JR., Zakaryae Fathi, Wayne F. Beyer, JR., Mark Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan
-
Patent number: 10670874Abstract: An optical computed tomography system for comprehensive end-to-end verification of the delivered dose in phantoms is described. The optical computed tomography system includes a light source that emits light; a detector; and a light-collimating tank arranged between the light source and the detector. The light-collimating tank itself includes a transparent substrate having a recessed region formed therein; an incident light surface formed on the transparent substrate; and an exit light surface formed on the transparent substrate opposite the incident light surface and shaped to focus light toward a focal region located outside of the transparent substrate. In some configurations, the incident light surface is shaped to collimate light impinging on the incident light surface into parallel rays that pass through the tank towards the exit light surface.Type: GrantFiled: March 30, 2018Date of Patent: June 2, 2020Assignee: Duke UniversityInventors: Mark Oldham, Devin Miles
-
Patent number: 10617892Abstract: A method for generating a radiation dose map of a dosimeter indicating a spatial distribution of radiation dose imparted to the dosimeter. The corrected radiation dose map may be generated with the computer system by applying temporal correction factor and spatial correction factors to a measured radiation dose map, the corrected radiation dose map having pixel values associated with the measured radiation dose having been corrected for temporal effects caused by changes in the measure of radiation dose imparted to the dosimeter between the first time point and the second time point, and for spatial effects caused by the sensitivity of the dosimeter to radiation measurements as a function of the spatial dimension.Type: GrantFiled: March 30, 2018Date of Patent: April 14, 2020Assignee: Duke UniversityInventors: Mark Oldham, Stewart Biedeman Mein, IV
-
Patent number: 10596387Abstract: A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.Type: GrantFiled: April 22, 2015Date of Patent: March 24, 2020Assignees: IMMUNOLIGHT, LLC., DUKE UNIVERSITYInventors: Harold Walder, Frederic A. Bourke, Zakaryae Fathi, Wayne F. Beyer, Mark W. Dewhirst, Mark Oldham, Justus Adamson, Michael Nolan